Skip to main content
main-content

Infectious disease

Latest articles

03-05-2019 | Rheumatology | News | Article

Meta-analysis supports increased herpes zoster risk with JAK inhibitors

Findings from a systematic review and meta-analysis indicate that the incidence of herpes zoster among rheumatoid arthritis patients treated with Janus kinase inhibitors is higher than expected in this population, and baricitinib is associated with a significantly increased risk.

29-03-2019 | Oncology | News | Article

Flu vaccine not contraindicated for checkpoint inhibitor-treated cancer patients

A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.

13-02-2019 | Oncology | News | Article

Immune checkpoint inhibitors viable in advanced cancer complicated by HIV

Immune checkpoint inhibitor therapy is well tolerated by patients with HIV infection and advanced-stage cancer and does not appear to adversely affect HIV viral load or CD4 cell count, suggest results of a systematic data review.

25-01-2019 | Oncology | News | Article

Hepatitis screening “may be warranted” following cancer diagnosis

The prevalence of hepatitis B virus and hepatitis C virus infection in patients with newly diagnosed cancer is similar to that of the US population, but a “substantial proportion” of patients are unaware of their infection, research shows.

01-11-2018 | Oncology | News | Article

Anti-PD-1 immunotherapy feasible for patients with HIV and cancer

A database analysis reported at the ESMO 2018 Congress in Munich, Germany, points to the feasibility of using immune checkpoint inhibitors in people living with HIV who develop cancer.

15-10-2018 | Oncology | Main feed | News

HPV vaccination age expanded in the USA

Click here for details

12-09-2018 | Leukaemia | News | Article

Levofloxacin reduces bacteremia during chemotherapy for childhood leukemia

Levofloxacin prophylaxis significantly reduces the risk for bacteremia among children receiving intensive chemotherapy for acute leukemia, but not among those undergoing hematopoietic stem cell transplantation, study data show.

14-08-2018 | Oncology | News | Article

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

03-08-2018 | HBV | News | Article

HCC risk score developed for patients with chronic hepatitis B virus

Researchers have developed and validated a score for predicting the risk for hepatocellular carcinoma in Asian patients with chronic hepatitis B virus infection who are taking oral antiviral therapy.

03-08-2018 | HBV | News | Article

HCC risk remains even after achieving positive HBV outcomes

Two meta-analyses published in the Journal of Viral Hepatitis confirm that patients with hepatitis B virus infection remain at risk for hepatocellular carcinoma even after achieving positive virologic outcomes, and identify factors associated with the risk.

03-08-2018 | HBV | News | Article

Global HBV prevalence estimated at 3.9%

More than 290 million people, or 3.9% of the global population, are infected with hepatitis B virus, and while efforts to combat infection are improving, greater access to diagnosis and treatment is needed to meet global targets, report The Polaris Observatory Collaborators.

03-05-2018 | HBV | News | Article

Updated AASLD guidance released on HBV prevention, diagnosis, and treatment

The American Association for the Study of Liver Diseases has issued a guidance statement for chronic hepatitis B virus, covering topics ranging from screening and prevention through to the clinical management of patients.

03-05-2018 | HBV | News | Article

End of treatment HBsAg levels may predict HBV relapse

Hepatitis B surface antigen levels at the end of treatment or prophylaxis with nucleos(t)ide analog inhibitors could be a useful indicator of hepatitis B virus relapse, suggest two Taiwanese studies.

03-05-2018 | HBV | News | Article

‘Excellent’ survival with long-term TDF, entecavir treatment of chronic HBV

Caucasian patients with chronic hepatitis B virus infection who receive long-term therapy with tenofovir disoproxil fumarate or entecavir have “excellent” survival, which is comparable to that of the general population, say researchers.

01-02-2018 | HBV | News | Article

ACP, CDC issue HBV vaccination, screening best practice advice

The American College of Physicians and Centers for Disease Control and Prevention have released best practice guidance for hepatitis B virus vaccination, screening, and linkage to care.

01-02-2018 | HBV | News | Article

Diabetes linked to elevated HCC risk after HBsAg seroclearance

Diabetes remains an independent risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection even after hepatitis B surface antigen seroclearance, findings indicate.

01-02-2018 | HBV | News | Article

Estimates of HBV carrier numbers in Japan released

Japanese researchers have generated a nationwide estimate of total numbers of hepatitis B virus carriers and treated patients in 2011, comparing it with earlier estimates from 2000.

22-12-2017 | HBV | News | Article

FIB-4 index identifies chronic HBV patients with lowest HCC risk

The noninvasive fibrosis-4 index can further refine the existing favorable clinical profile for hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B virus infection and help identify those with the lowest risk, say researchers.

22-12-2017 | HBV | News | Article

Serum HBV RNA may represent noninvasive marker for HBV progression

Serum hepatitis B virus RNA levels correlate with viral transcriptional activity and histologic changes in the livers of patients with chronic HBV who are receiving nucleos(t)ide analog therapy, Chinese researchers report.

15-12-2017 | HBV | News | Article

Durability of HBsAg clearance induced by NA therapy demonstrated

Clearance of hepatitis B surface antigen with nucleos(t)ide analogs is as durable as spontaneous clearance in patients with chronic hepatitis B virus infection, researchers report.

Image Credits